Earlier this year at the World Orphan Drug Congress Asia 2013 Oved Amitay, Vice President, Head of Commercial , Alnylam Pharamceutical delivered the presentation: Successful partnering strategies for accelerating development and improving patient access in Asia.
The contents of this presentation is as follows:
- Alnylam is creating a new class of high impact therapies, using powerful and natural mechanism known as RNAi, to significantly improve the lives of patients
- Development strategy focuses on genetically defined target/disease
- Commercialization strategy to maximize value centers on high unmet need indications, concentrated market access and strong patient advocacy
- Strategy for lead programs is to commercialize directly in North America, South America and Europe
- »TTR-mediated amyloidosis, hemophilia, and porphyria (AIP)
- Selectively partner in Asian markets to accelerate development and improve patient access to transformative therapies